Bothell-based BioLife Solutions’ CryoStor® integrated in Kolon group’s cell-mediated gene therapy for Osteoarthritis

Bothell-based BioLife Solutions, Inc. today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science.

  • Wednesday, August 24, 2016 4:30pm
  • Business

Bothell-based BioLife Solutions, Inc. today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science.

The Kolon Group subsidiary filed as of July 8 a biologics license application (BLA) for Invossa with the Korean Ministry of Food and Drug Safety. According to Kolon, Invossa is the world’s first cell-mediated gene therapy for osteoarthritis, a degenerative joint disease affecting more than 150 million people. The product was developed by US-based TissueGene, Inc. as “TissueGene-C” and is administered via intra-articular injection without the need for anesthesia or surgical intervention. The therapy has demonstrated effectiveness in providing pain and symptomatic relief as well as in delaying the disease’s structural progression.

“Kolon’s BLA submission seeking approval to market Invossa in Korea is encouraging news for millions of patients suffering from osteoarthritis,” said BioLife President and CEO Mike Rice. “We are very pleased that TissueGene and Kolon have selected CryoStor as the best in class biopreservation media for commercializing Invossa. CryoStor and HypoThermosol®, our cell and tissue storage and shipping media, are now incorporated into more than 220 pre-clinical validations and clinical trials of cell-based therapies, targeting blood cancers, solid tumors, vision loss, heart disease, stroke, and movement disorders such as osteoarthritis. We look forward to progress by Kolon and other customers in gaining regulatory approvals to commence commercial manufacturing of these life-changing and life-saving cell therapies.”

More in Business

Bothell chamber of commerce changes name to include Kenmore

The Bothell chamber of commerce has been re-branded to include its neighboring… Continue reading

CitySurf pop-up pool could open this summer on Eastside

A Sammamish couple hopes to break ground on a permanent indoor surf facility later this year.

Real estate embraces the digital era in creative ways

Kirkland’s MainStreet Property Group’s Junction Apartments in downtown Bothell topic of discussion at recent real estate symposium.

Two wineries move in with Teatro ZinZanni

Two local wineries will be sharing the old Redhook brewery in Woodinville with Teatro ZinZanni.

Bothell-Kenmore Reporter transitions to subscription model

The pre-paid subscriptions will be $39 a year or $3.99 monthly.

Sound Publishing appoints new president and vice president

Josh O’Connor is the new president and publisher while Terry Ward is the new vice president.

Seattle head tax worries Eastside business organizations

Seattle has passed a head tax to help fund homelessness services.

Office space is tight all across the Eastside

The Broderick Group released a report detailing low office vacancy rates across Eastside cities.

Local pot stores bringing in the green

Bothell’s marijuana retail stores have done well recently.

Country Village businesses face an uncertain future

Country Village will be open for another year, but business owners are thinking of the future.

Solar business moves in to Kenmore

Northwest Electric and Solar is open for business in Kenmore following a move from Seattle.

AGC Biologics appoints new head of Bothell operations

Jin Wang, Ph.D. was named site head general manager.